NCT00659971View on ClinicalTrials.gov

Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis

PHASE2CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Oral Candidiasis
Interventions
DRUG

PAC113

PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days

Trial Locations (1)

28078

Rosedale Infectious Disease, Huntersville

Sponsors
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Pacgen Biopharmaceuticals Corporation

INDUSTRY